Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Trial · NCT02207634
Adverse events678
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 678
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Placebo | 74 | 990 | |
| other | Nasopharyngitis | Infections and infestations | Evolocumab | 101 | 983 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo | 63 | 990 | |
| other | Upper respiratory tract infection | Infections and infestations | Evolocumab | 53 | 983 | |
| other | Diabetes mellitus | Metabolism and nutrition disorders | Placebo | 59 | 990 | |
| other | Diabetes mellitus | Metabolism and nutrition disorders | Evolocumab | 45 | 983 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Placebo | 36 | 990 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Evolocumab | 58 | 983 | |
| other | Hypertension | Vascular disorders | Placebo | 66 | 990 | |
| other | Hypertension | Vascular disorders | Evolocumab | 61 | 983 | |
| serious | Anaemia | Blood and lymphatic system disorders | Placebo | 6 | 990 | |
| serious | Anaemia | Blood and lymphatic system disorders | Evolocumab | 2 | 983 | |
| serious | Autoimmune haemolytic anaemia | Blood and lymphatic system disorders | Placebo | 1 | 990 | |
| serious | Autoimmune haemolytic anaemia | Blood and lymphatic system disorders | Evolocumab | 0 | 983 | |
| serious | Febrile neutropenia | Blood and lymphatic system disorders | Placebo | 0 | 990 | |
| serious | Febrile neutropenia | Blood and lymphatic system disorders | Evolocumab | 1 | 983 | |
| serious | Haemorrhagic anaemia | Blood and lymphatic system disorders | Placebo | 0 | 990 | |
| serious | Haemorrhagic anaemia | Blood and lymphatic system disorders | Evolocumab | 1 | 983 | |
| serious | Immune thrombocytopenic purpura | Blood and lymphatic system disorders | Placebo | 0 | 990 | |
| serious | Immune thrombocytopenic purpura | Blood and lymphatic system disorders | Evolocumab | 1 | 983 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02207634/events